eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
1-2/2005
vol. 30
 
Share:
Share:
more
 
 
abstract:

Serological markers for hepatocellular carcinoma – modern trends

Kazimierz Madaliński
,
Maria Jończyk
,
Jolanta Rybczyńska
,
Marta Wawrzynowicz-Syczewska
,
Anna Boroń-Kaczmarska

Centr Eur J Immunol 2005; 30 (1-2): 32-36
Online publish date: 2006/07/26
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Imaging techniques [ultrasonography (USG), computer tomography (CT) and nuclear magnetic resonance (NMR)] are still the most important element for surveillance of liver cirrhosis patients in the detection of primary liver cancer. However, in order to improve the sensitivity, specificity and predictive value of the diagnostic process, the determination of several serological markers of cancers must be included. For example, the sensitivity of a combined USG examination and AFP determination exceeds 92%. The serological tests proposed by us for the detection of hepatocellular carcinoma (HCC) include alfa-fetoprotein (AFP), alfa-L-fucosidase (AFU), and anti-p53 antibody tests. Their value depends mainly on the sensitivity and specificity of AFU and AFP tests. It should be underlined that the AFU method achieves better parameters for the detection of HCC than the AFP test. The increased detection rate of anti-p53 antibodies is found not only in patients with primary liver cancer, but also in carcinomas of the other digestive tract organs; thus, this test lacks specificity for HCC. Finally, the costs of surveillance of patients with LC for HCC are rather high, and limit the broader use of surveillance
keywords:

hepatocellular carcinoma (HCC), alpha-fetoprotein, alpha-fucosidase, anti-p53 antibodies, costs of HCC surveillance

Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.